Abstract
Programmed cell death (apoptosis) is a key tumor suppressor mechanism. Consequently, most if not all cancers develop mechanisms to abolish or circumvent this genetic program. Besides enabling malignant transformation and tumor progression, defects in apoptosis can result in resistance to cytotoxic cancer therapies. Much progress has been made in the delineation of the molecular pathways leading to apoptosis. This allows the identification of target molecules and lead compounds to develop novel therapies, which make use of this intrinsic death program for the treatment of cancer. Here, we review the current understanding of apoptotic signal transduction pathways, and strategies of their therapeutic modulation in relation to lymphoma and other cancers.
Keywords: BH3-only proteins, p53 Gene Transfer, pro-apoptotic genes, TNF receptor superfamily, Mouse-double-minute-2 (MDM-2)
Current Drug Targets
Title: Therapeutic Targeting of Apoptotic Pathways in Cancer
Volume: 7 Issue: 10
Author(s): Johannes Meiler and Martin Schuler
Affiliation:
Keywords: BH3-only proteins, p53 Gene Transfer, pro-apoptotic genes, TNF receptor superfamily, Mouse-double-minute-2 (MDM-2)
Abstract: Programmed cell death (apoptosis) is a key tumor suppressor mechanism. Consequently, most if not all cancers develop mechanisms to abolish or circumvent this genetic program. Besides enabling malignant transformation and tumor progression, defects in apoptosis can result in resistance to cytotoxic cancer therapies. Much progress has been made in the delineation of the molecular pathways leading to apoptosis. This allows the identification of target molecules and lead compounds to develop novel therapies, which make use of this intrinsic death program for the treatment of cancer. Here, we review the current understanding of apoptotic signal transduction pathways, and strategies of their therapeutic modulation in relation to lymphoma and other cancers.
Export Options
About this article
Cite this article as:
Meiler Johannes and Schuler Martin, Therapeutic Targeting of Apoptotic Pathways in Cancer, Current Drug Targets 2006; 7 (10) . https://dx.doi.org/10.2174/138945006778559175
DOI https://dx.doi.org/10.2174/138945006778559175 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
Emerging Drug Targets and Revolutionary Therapeutic Approaches for Effective Anti-Cancer Intervention
Recent advancements in cancer research have significantly advanced our understanding of the intricate molecular mechanisms driving cancer progression, leading to the identification of new drug targets and therapeutic strategies. The elucidation of complex signaling pathways and genetic aberrations associated with tumorigenesis has provided valuable insights into potential targets for intervention. ...read more
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
Progress in Drug Delivery, Therapeutic Strategies, and Nursing Practices: Enhancing Diagnostics and Clinical Outcomes in Complex Diseases
The recent advancements in drug delivery systems as well as therapeutics have significantly improved therapy effectiveness combined with better patient results specifically for difficult disease management. The modern pharmaceutical research field makes drug targeting its main priority because this approach strengthens therapeutic agents' precision while improving their effectiveness. Multiple delivery ...read more

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
An Updated Review on Molecular Biomarkers in Diagnosis and Therapy
of Colorectal Cancer
Current Cancer Drug Targets Recent Developments in Patented DC-Based Immunotherapy for Various Malignancies
Recent Patents on Regenerative Medicine Second-line Treatment of Advanced Non-small Cell Lung Cancer Non-oncogene Addicted: New Treatment Algorithm in the Era of Novel Immunotherapy
Current Clinical Pharmacology Current Treatment Strategies for Multiple Sclerosis - Efficacy Versus Neurological Adverse Effects
Current Pharmaceutical Design Multiple Myeloma and the Immune Microenvironment
Current Cancer Drug Targets The Prevention of Oral Mucositis in Patients with Blood Cancers: Current Concepts and Emerging Landscapes
Cardiovascular & Hematological Agents in Medicinal Chemistry Current Technological Development of Antibody Therapeutics
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) CDK Inhibitors: From the Bench to Clinical Trials
Current Drug Targets Targeting Angiogenic Genes as a Therapeutic Approach for Hepatocellular Carcinoma
Current Gene Therapy Potential Role of Bioactive Lipids in Rheumatoid Arthritis
Current Pharmaceutical Design Radiologic Findings of IgG4-Related Disease
Current Immunology Reviews (Discontinued) From Proteins to Nucleic Acid-Based Drugs: The Role of Biotech in Anti-VEGF Therapy
Anti-Cancer Agents in Medicinal Chemistry CDK-associated Cullin 1 Promotes Cell Proliferation and Inhibits Cell Apoptosis in Human Glioblastoma
Current Cancer Drug Targets Diffuse Large B-Cell Lymphoma with Involvement of the Chest Wall
Current Respiratory Medicine Reviews Breast Cancer Resistance Protein and P-Glycoprotein in Brain Cancer: Two Gatekeepers Team Up
Current Pharmaceutical Design TEM8 Targeted Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry HERVs Role in the Pathogenesis, Diagnosis or Prognosis of Aging Diseases: A Systematic Review
Current Molecular Medicine Signaling in Human B-Lymphoma Rafts
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Effect of Human Umbilical Cord Blood Progenitor Cells Versus Mononuclear Cells on Acute Renal Failure Rat Model
Current Stem Cell Research & Therapy The Role of Growth Factors in the Prevention and Treatment of Chemotherapy-Induced Peripheral Neurotoxicity
Current Drug Safety